Our Philosophy
Leaders in Immunology
We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.
Our Science
We are led by experienced biopharma executives with exceptional track records of building strong companies, delivering innovative treatments and growing diverse teams.
The Right Blend
We have the right blend of experience, along with a broad network of contacts, needed to advance programs that can dramatically transform patients’ lives.
Why ACELYRIN
We are building a different kind of biopharma company focused on developing and delivering therapeutics through efficient and ongoing collaboration.
Our Network
ACELYRIN can access promising therapeutic programs through our global network of relationships across pharma and biotech, finance and academia.
Our Focus
We conduct a licensing and acquisition search process that is both directed and opportunistically focused on platforms, programs and products when compelling science or data exist.
Our Work
Accelerating Transformative Therapies
We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.
Partnering with ACELYRIN
Partnering with ACELYRIN
Partnering with ACELYRIN
For Investors
Maximizing Shareholder Value
For InvestorsIzokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis 
Publication
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Read more ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Read more